CRISPR Startup Gets $25M to Target Lp(a) and Triglycerides With One-Time Gene Edits
Scribe Therapeutics wins $25M in funding to advance two CRISPR programs targeting dangerous lipid drivers of heart disease toward clinical trials.
Summary
Scribe Therapeutics has received over $25 million from California's regenerative medicine institute to push two CRISPR gene-editing programs closer to human trials. The first, STX-1200, targets a gene responsible for elevated lipoprotein(a) — a stubborn cardiovascular risk factor that diet and most drugs cannot easily lower. The second, STX-1400, targets a gene linked to dangerously high triglycerides and a painful, life-threatening condition called acute pancreatitis. Both programs aim to deliver a single treatment that permanently corrects the underlying genetic problem. This approach differs from daily medications because the edit is designed to last a lifetime. The funding comes through California's CIRM preclinical program, which bridges lab discoveries to first-in-human studies.
Detailed Summary
Cardiovascular disease remains the leading cause of death globally, and two of its most treatment-resistant drivers — elevated lipoprotein(a) and severe hypertriglyceridemia — may soon have a new class of solution: one-time CRISPR gene edits. Scribe Therapeutics has secured more than $25 million from the California Institute for Regenerative Medicine to accelerate two preclinical programs toward clinical trials, marking a meaningful step in durable genetic medicine for lipid disorders.
The first program, STX-1200, targets the LPA gene to reduce lipoprotein(a), commonly called Lp(a). Elevated Lp(a) is a genetically inherited risk factor affecting roughly one in five people worldwide and is strongly associated with heart attack, stroke, and aortic valve disease. Unlike LDL cholesterol, Lp(a) cannot be meaningfully reduced through diet or standard statins, making a gene-editing solution particularly compelling. A single edit could theoretically lower Lp(a) for life.
The second program, STX-1400, targets APOC3, a gene that regulates triglyceride-rich lipoproteins. Overactive APOC3 is linked to familial chylomicronemia syndrome and severe hypertriglyceridemia — conditions that dramatically raise pancreatitis risk and cardiovascular burden. Existing RNA-based therapies require repeated dosing; a CRISPR edit could offer a one-time correction.
Both programs use Scribe's proprietary X-Editor XE platform, engineered for higher precision, editing efficiency, and in-vivo deliverability compared to standard CRISPR-Cas9 systems. They sit in the preclinical pipeline alongside STX-1150, Scribe's more advanced clinical-stage asset targeting sickle cell disease-adjacent pathways.
Important caveats apply. These programs are preclinical, meaning human efficacy and safety data do not yet exist. CRISPR therapies carry risks including off-target edits and immune responses. Clinical entry is likely years away. Still, for health-conscious individuals tracking cardiovascular risk, this represents a future where genetic cardiovascular vulnerabilities may be corrected permanently rather than managed chronically.
Key Findings
- STX-1200 uses CRISPR to permanently lower Lp(a), a genetic cardiovascular risk factor resistant to diet and statins.
- STX-1400 targets APOC3 to durably reduce triglycerides and prevent life-threatening pancreatitis in high-risk patients.
- Both therapies are designed as single-dose, lifetime treatments — a major shift from daily or monthly medications.
- CIRM awarded $25M+ to move both programs from lab research into human clinical trials.
- Scribe's X-Editor XE platform claims improved precision and deliverability over standard CRISPR-Cas9 systems.
Methodology
This is a news report summarizing a funding announcement from Scribe Therapeutics, as covered by Longevity.Technology. Evidence is based on company press materials and CIRM award documentation, not peer-reviewed clinical data. No independent scientific validation of platform claims is included.
Study Limitations
Both programs are preclinical with no human safety or efficacy data yet available. Claims about the X-Editor platform's superiority should be verified against peer-reviewed publications. Clinical availability is likely 5-10 years away pending successful trials and regulatory review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: